It seems eons ago when the first cattle rush for Minnesota's governor's office appeared on stage at the BIO forum in April. The results of that debate were abysmal for innovation. Eight months later, Tom Horner and Tom Emmer have substantially improved their grades.
After surveying the chaos otherwise known as Fall elections, I can confidently conclude one thing: I don't think Democrat gubernatorial candidate Mark Dayton is scoring a lot of votes from the business community, especially the important lifescience industry. So that leaves GOP nominee Tom Emmer and Independence Party favorite Tom Horner vying for lifescience votes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If Minnesota keeps this up, expanding the $60 million angel investment tax credit won't just be a nice idea, it will be a political necessity. Minnesota has awarded $1.5 million in credits to angels, up from $573,000 in late August -- a nearly three-fold increase in less than two months.
Strip away the politics, and we get a clearer picture. If government really wants to jump start job creation, then we really should look at helping startups, which account for 20 percent of total gross job creation.
I've been deeply skeptical of Tom Emmer's commitment to support high-tech innovation in Minnesota. At a BIO forum for candidates running for Minnesota governor, Emmer's lackluster performance earned him a big, juicy "F" from MedCity News. So it was a pleasant surprise when Emmer, now the Republican Party's nominee, debuted proposals earlier this week to boost job creation in the state.
A few months ago, LifeScience Alley and the BioBusiness Alliance of Minnesota sponsored the first ever BIO forum, a chance for the gazillion people seeking to succeed Gov. Tim Pawlenty to woo the bioscience crowd. The results were dismal. The only candidate from that group with a strong chance of winning the election, the Republican […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.